Published in Surgery on February 01, 2002
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer (2003) 1.18
The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol (2011) 0.94
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother (2013) 0.89
Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. PLoS One (2012) 0.84
Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg (2012) 0.84
Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. Can J Gastroenterol (2008) 0.83
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) (2016) 0.78
Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Technol Cancer Res Treat (2016) 0.76
Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res (2016) 0.75
T-cell programming in pancreatic adenocarcinoma: a review. Cancer Gene Ther (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Optimized speckle variance OCT imaging of microvasculature. Opt Lett (2010) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas (2004) 2.30
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res (2009) 2.12
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 2.11
Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck (2014) 2.10
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas (2007) 1.54
Robust hydrocarbon degradation and dynamics of bacterial communities during nutrient-enhanced oil spill bioremediation. Appl Environ Microbiol (2002) 1.49
Evolving surgical techniques of and indications for corneal transplantation in Ontario from 2000 to 2009. Can J Ophthalmol (2011) 1.48
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery (2010) 1.45
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
The PMAIP1 gene on chromosome 18 is a candidate tumor suppressor gene in human pancreatic cancer. Dig Dis Sci (2008) 1.40
Pharyngo-colostomy with supraglottic partial laryngectomy in caustic oropharyngeal stricture. Ann Thorac Surg (2006) 1.39
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut (2010) 1.35
Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer (2008) 1.35
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck (2012) 1.30
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett (2004) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun (2010) 1.28
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22
Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) (2006) 1.22
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Current status of surgery for pancreatic cancer. Dig Surg (2007) 1.21
In vivo diagnosis of oral dysplasia and malignancy using optical coherence tomography: preliminary studies in 50 patients. Lasers Surg Med (2009) 1.21
Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck (2007) 1.19
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc (2008) 1.17
Acute pancreatitis due to pancreatic arteriovenous malformation: 2 case reports and review of the literature. Pancreas (2006) 1.16
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
Ability of optical coherence tomography to detect caries beneath commonly used dental sealants. Lasers Surg Med (2010) 1.10
Tumor-cell death, autophagy, and immunity. N Engl J Med (2012) 1.10
Nutrient and oxygen concentrations within the sediments of an Alaskan beach polluted with the Exxon Valdez oil spill. Environ Sci Technol (2010) 1.09
Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology (2008) 1.08
Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas (2005) 1.08
HMGB1 as an autophagy sensor in oxidative stress. Autophagy (2011) 1.08
Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest (2015) 1.08
The Tohoku Medical Megabank Project: Design and Mission. J Epidemiol (2016) 1.08
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med (2010) 1.07
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol (2006) 1.07
Adverse Drug Reactions in Children--International Surveillance and Evaluation (ADVISE): a multicentre cohort study. Drug Saf (2012) 1.07
miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol (2013) 1.07
MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol (2010) 1.06
Optimization of glucose level to determine the stimulation index of isolated rat islets. Pancreas (2008) 1.06
The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal (2011) 1.05
Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol (2012) 1.04
Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol (2009) 1.04
Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas (2007) 1.04
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol (2012) 1.03
Effect of dispersant on the composition of the water-accommodated fraction of crude oil and its toxicity to larval marine fish. Environ Toxicol Chem (2005) 1.02